Gastroenterology

To celebrate the close of 2024, we're recapping the 10 most popular approval articles across the HCPLive Network of brands.

This year in review spotlights top GI FDA news from 2024 and new clinical guidance from the American Gastroenterological Association.

Post-hoc analysis findings suggest tenapanor improves both abdominal and bowel symptoms in adult patients with IBS-C.

Frissora reviews findings from a cost-effectiveness analysis comparing the Vibrant System to linaclotide for CIC management.

The sBLA seeks to expand golimumab’s approval for UC to include pediatric patients ≥ 2 years of age and is supported by data from the PURSUIT program.

Positive phase 2b data show duvakitug met primary endpoints for clinical remission in ulcerative colitis and endoscopic response in Crohn disease.

Elevated blood insulin levels and insulin resistance each contributed to an elevated risk of colorectal cancer, a new study finds.

A study shows constipation has a causal relationship with schizophrenia and MDD, but the relationship with schizophrenia may have limited clinical implications.

Patients with IBS had different dietary patterns than matched general population controls, with poor diet diversity and quality linked to symptom severity.

Study findings highlight systemic and local autonomic imbalance in patients with IBS-C, pointing to the value of autonomic modulation in this population.

This month in review spotlights GI pipeline updates and news from the 2024 NASPGHAN and ACG annual meetings.

Previous ASA guidance recommended holding GLP-1 RAs in the perioperative period, but new 2024 multisociety guidance suggests a risk-based approach.

An overview and landing page for future installments from HCPLive's 8th annual This Year in Medicine Series.

The supplemental Biologics License Application is supported by the phase 3 ASTRO study of guselkumab SC induction therapy in ulcerative colitis.

HCPLive spoke with Kastl at NASPGHAN about the team’s study on the immune response to the COVID-19 vaccination among children with IBD.

At NASPGHAN, HCPLive spoke to Hamant about her team’s study that showed their algorithm was linked to increased VTE Prophylaxis among Pediatric IBD.

Bifidobacterium longum 35624TM reduces IBS symptom severity in children and adolescents, according to a study presented at NASPGHAN 2024.

At NASPGHAN 2024, HCPLive spoke with Duncan about how treating infants who appear to have reflux may actually result in greater repeat hospital visits.

GERD diagnoses in BRUE infants were linked to frequent acid suppression use and repeat hospital visits, according to a study presented at NASPGHAN 2024.

HCPLive spoke with Lat at NASPGHAN 2024 about how for communities with high H. pylori prevalence, it is best to test for H. pylori before a colonoscopy.

At NASPGHAN 2024, Okuno shared findings on reduced parental stress after children’s tube weaning, emphasizing the potential for new outpatient weaning protocols.

HCPLive spoke with Okuno at NASPGHAN 2024 about a study examining changes in parent stress levels and mental health symptoms after a child completes weaning off tube feeding.

At NASPGHAN, HCPLive spoke with Margolis about her team’s study on the link between maternal SSRI exposure and an infant’s development of gut-brain interaction disorders.

Maternal SSRI use was linked to a higher risk of constipation in infants, while untreated maternal depression was tied to colic. Margolis discussed these findings at NASPGHAN.